Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
loncastuximab tesirine + rituximab
- Development stage
- Unknown
- Lead developer
- ADC Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Loncastuximab tesirine + rituximab is a combination therapy under investigation for the treatment of relapsed or refractory follicular lymphoma. Loncastuximab tesirine is an antibody–drug conjugate (ADC) consisting of a humanized anti-CD19 monoclonal antibody linked to a pyrrolobenzodiazepine dimer toxin (tesirine), which acts as a DNA cross-linking agent. Rituximab is a monoclonal antibody targeting CD20 on B cells, mediating cytotoxicity through immune mechanisms. The combination leverages the direct cytotoxic effect of loncastuximab tesirine and the immune-mediated effects of rituximab, with preclinical and clinical data suggesting synergistic activity between these agents[2][3][4][5][6]. ADC Therapeutics developed loncastuximab tesirine, which is FDA-approved as monotherapy for relapsed/refractory large B-cell lymphoma; its use in combination with rituximab for follicular lymphoma remains investigational[6].
- Brand names
- ZYNLONTA + rituximab
- Other names
- loncastuximab tesirine-lpyl + rituximab
02
Targets
Beyond the preview
Go deeper on loncastuximab tesirine + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on loncastuximab tesirine + rituximab.